Hyperoxaluria and oxalosis

Doctors and departments

Mayo Clinic is active in several areas of research on hyperoxaluria, coordinated through the Mayo Clinic Hyperoxaluria Center and the Rare Kidney Stone Consortium in Rochester, Minnesota. The center maintains an international registry of data on people with hyperoxaluria, compiles statistics on outcomes, and maintains a bank of urine, plasma, blood and liver samples for investigation and collaborative research.

The center offers people the opportunity to participate in clinical trials, testing new diagnosis and treatment approaches.

Ongoing research projects include:

• Use of active patient registries for primary and enteric hyperoxaluria to improve the understanding of these two diseases.
• Identification of genetic changes, also called genetic mutations, in primary hyperoxaluria and other genetic causes of kidney stone disease or nephrocalcinosis, including correlation of genetic changes with disease outcomes.
• Evaluation of new treatments for primary hyperoxaluria, including use of newer agents such as small inhibitory RNAs that block oxalate synthesis in the liver.
• Evaluation of new treatments for enteric hyperoxaluria, including treatments taken by mouth, also called orally administered, of oxalate-degrading enzymes and bacteria.
• Evaluation of the effect of diet and calcium intake on urine oxalate levels.
• Development of new technology for measuring the type of kidney stones on computerized tomography (CT) scans and the ability to fragment them using urologic devices.
• Improvement of quality of life in patients with primary hyperoxaluria and other people who develop kidney stones.

See a list of publications about hyperoxaluria by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.